BioMarin Pharmaceutical Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $348.9M | $426.9M | $167.6M | $141.6M | $-64.1M | $854.0M | $-23.8M | $-77.2M |
| Depreciation & Amortization | $79.6M | $96.4M | $104.4M | $102.0M | $108.0M | $105.2M | $105.3M | $95.7M |
| Depreciation | $48.5M | $46.6M | $40.3M | $38.6M | $46.1M | $43.0M | $51.8M | $90.4M |
| Amortization | $19.4M | $43.3M | $62.2M | $67.2M | — | — | — | — |
| Stock-Based Compensation | $181.4M | $201.6M | $207.1M | $196.3M | $197.3M | $189.7M | $159.9M | $148.8M |
| Net Cash from Operating Activities | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M | $85.4M | $48.3M | $20.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $103.0M | $85.4M | $96.7M | $121.0M | $95.6M | $114.3M | $145.0M | $144.6M |
| Business Acquisitions | — | — | — | — | — | — | — | $0 |
| Net Cash from Investing Activities | $-414.2M | $136.5M | $-111.2M | $-20.0M | $-366.3M | $-53.6M | $-31.0M | $264.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | $0 | $0 | $50.0M | $0 | $0 |
| Net Cash from Financing Activities | $-42.4M | $-526.4M | $-18.7M | $-18.7M | $-48.0K | $181.1M | $-74.7M | $-388.0M |
| Net Change in Cash | $368.8M | $187.7M | $30.6M | $137.3M | $-61.9M | $211.7M | $-56.5M | $-104.0M |
| Free Cash Flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M | $-28.9M | $-96.8M | $-124.4M |